Nearly half of Alzheimer’s disease patients treated with TrueBinding’s investigational therapy TB006 for at least three months showed…
Articles by Steve Bryson, PhD
An innovation passport, the first step in the U.K.’s Innovative Licensing and Access Pathway (ILAP) — intended to accelerate the…
DISCERN, a biomarker test reported to accurately diagnose Alzheimer’s disease at its earliest stages, routinely would be used by 90%…
Lecanemab (BAN2401), an amyloid-targeted antibody therapy for early Alzheimer’s disease, has been granted priority review in Japan, according…
About 1.5 years of treatment with lecanemab (BAN2401) — now under regulatory review in the U.S. — was found to…
The experimental therapy gantenerumab did not significantly slow clinical decline in people with early Alzheimer’s disease, failing to…
Three years of a daily multivitamin-mineral supplement improved memory, and cognitive and executive function in older adults, according to data…
The toxic clumping of amyloid-beta, one of two key proteins implicated in Alzheimer’s disease, causes living human cells to…
Higher levels of small high-density lipoprotein (HDL), known as “good cholesterol,” in the fluid surrounding the brain and spinal cord…
Improved access to high-quality healthcare and research for Latinos living with Alzheimer’s disease and related dementia are needed, according…